Iosbio Ltd

The rapid development, manufacture and supply of mRNA vaccines against COVID-19 is one of the greatest success stories in modern medicine. Demonstrably safe and effective in over billion patients, the question now is not if, but how quickly, this revolutionary combination of an mRNA therapy and lipid nanoparticle (LNP) carrier can be expanded to and explo...

iosBio has developed a technology which enables the oral administration of thermally stable vaccines. We will utilise this technology to develop a candidate EV68 vaccine, a disease identified as having the potential to cause epidemics.

IosBio has developed a technology which enables the generation of thermally stable, orally administered vaccines. We will utilise this technology to develop a candidate Nipah vaccine, a disease identified as having pandemic potential.

Bacterial pathogens of fresh produce are responsible for substantial losses through disease, damage and failure to meet market specifications, with no specific controls. Diseased crop and waste-food disposal, plus additional agricultural land and water required to achieve sufficient marketable yields all add up to increase the carbon footprint of food pro...

“During the Phase 1 Innovate UK funded programme Stabilitech demonstrated that a thermally stabilised oral capsule delivering a vaccine-inducing viral vector to the gastrointestinal tract can stimulating systemic immunity. In these studies, the viral vector was designed to transduce expression of Zika virus antigens, giving rise to specific antibodies pro...

Oral delivery of low cost viral Zika vaccine antigens which generate authentic humoral responses. The ability to deliver a vaccine orally in a reliable manner has several obvious advantages. However, barriers exist which limit this route of administration. Two of the main barriers include the highly acidic environment in the stomach and the hold time of p...

Varicella Zoster virus (VZV) is the causative agent of shingles and chicken pox. The live attenuated VZV vaccine is susceptibe to degradation during its manufacture representing a significant technical formulation challenge that is limiting the broader use of the vaccine, as well as impacting on its cost. Stabilitech has a novel stabilisation platform whi...

Effective and safe manufacture of human cells for therapy requires application of multiple-input, Quality by Design principles throughout the whole process, from cell sourcing through expansion to patient. Particularly important are hold stages which are essential for flexibility, the poor specification of which will be the cause of process failures and l...

Awaiting Public Summary